This bill adds a new federal offense to Title 18 that targets the use of drugs to end pregnancy, with narrow exceptions for contraception given before conception, miscarriage treatment, and physician-certified life‑threatening conditions. It also amends chapter headings and statutory definitions to treat an unborn child as beginning at fertilization.
The proposal reaches manufacturers, pharmacies, clinicians and any intermediary that prescribes, dispenses, distributes, or sells a medication used to induce abortion. By placing criminal penalties into the federal criminal code for conduct tied to medication abortion, the bill creates a national prohibition that would operate alongside—or in direct tension with—existing FDA approvals, state law variations, and telehealth/mail-order medical practice models.
At a Glance
What It Does
Creates a new section in chapter 74 of Title 18 making it a federal crime to prescribe, dispense, distribute, or sell a drug intended to procure an abortion, while carving out limited clinical exceptions. It also renames chapter 74 and inserts new statutory definitions of pregnancy and unborn child.
Who It Affects
Manufacturers of mifepristone and misoprostol, pharmacies (including mail-order and retail), clinicians who prescribe medication abortion (including telemedicine providers), and distributors involved in shipping such drugs across state lines.
Why It Matters
The bill shifts access to medication abortion from a regulatory question handled by FDA and states into the federal criminal arena, raising immediate compliance, liability, and interstate‑commerce issues for healthcare providers, drug distributors, and payers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a standalone federal offense into the criminal code that targets drugs used to induce abortion. It makes illegal the act of prescribing, dispensing, distributing, or selling any drug, medication, or chemical when the actor’s purpose is to procure an abortion.
The statute includes a set of express exceptions and a definitional section that frames pregnancy and the unborn child to begin at fertilization.
Rather than rely on administrative or civil remedies, the bill makes prohibited conduct subject to federal criminal prosecution. It bars criminal prosecution of the pregnant woman who receives a chemical abortion, but it does not immunize anyone who aids her (clinicians, pharmacies, or distributors).
One of the statutory exceptions covers contraceptives given before conception or before pregnancy can be confirmed; another covers treatment of miscarriage “according to medical guidelines as accepted as of the date of the miscarriage;” a third permits interventions necessary where a physician certifies the pregnancy poses a danger of death.The definitions change the starting point for pregnancy and unborn-child status to fertilization and incorporate the statutory ‘‘born alive’’ reference from title 1. The bill’s language—“notwithstanding any other provision of law”—signals that Congress intends this federal criminal prohibition to apply even where other federal statutes or agency actions (including FDA approvals and labeling) might authorize distribution or use of a drug.
Practically, that raises questions about whether an FDA‑approved product may nonetheless be the focus of federal criminal enforcement if used to procure an abortion. The range of covered conduct explicitly lists prescribing and selling as well as distribution, which captures modern channels such as telehealth prescribing and shipment of medicines by mail.
The Five Things You Need to Know
The statute makes unlawful the act of prescribing, dispensing, distributing, or selling any drug or chemical for the purpose of procuring an abortion.
A violator faces a federal criminal penalty of imprisonment for not more than 25 years, a fine under Title 18, or both.
Exceptions include contraceptives administered before conception or before pregnancy can be confirmed, treatment of miscarriage under contemporaneous medical guidelines, and physician‑certified interventions necessary to prevent death.
The bill expressly prohibits criminal prosecution of the pregnant woman who obtains or attempts to obtain a chemical abortion; it does not extend that bar to providers or distributors.
The bill defines pregnancy and unborn child to begin at fertilization and ties the term ‘born alive’ to the Title 1 definition, meaning the statutory protection extends from fertilization through birth.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
States the act’s name, the ‘‘Ending Chemical Abortions Act of 2025.’
Findings
Lists factual assertions about FDA actions and the rise of medication abortion; findings are not operative law but frame legislative intent. Those findings indicate Congress’s stated rationale for federal action and will matter for statutory interpretation disputes, but do not themselves change regulatory authority or create private rights.
Renames Chapter 74
Amends the table of chapters in Part I of Title 18 to retitle Chapter 74 as ‘Abortion crimes.’ This clerical change signals Congress’s intent to group the new offense with other federal abortion‑related criminal provisions, which could influence how prosecutors and courts view the statute in relation to existing §§1531 and surrounding provisions.
Core prohibition (prescribe/dispense/distribute/sell)
Adds the operative criminal prohibition: any person who prescribes, dispenses, distributes, or sells a drug, medication, or chemical for the purpose of procuring an abortion commits a federal offense. The statutory text captures a broad set of actors and channels—clinicians, pharmacies, manufacturers, and intermediaries—and uses mens rea tied to purpose, which raises evidentiary questions about intent and lawful medical practice.
Narrow clinical exceptions, immunity for woman, and new definitions
Provides three express exceptions (pre‑conception contraception, miscarriage treatment consistent with then‑accepted guidelines, and life‑threatening pregnancy certified by a physician). It bars criminal prosecution of the pregnant woman but not third parties. The definitions language places pregnancy at fertilization and references the Title 1 ‘born alive’ definition, legally anchoring protection from fertilization onward and affecting how the statute applies to early‑term clinical decisions and research.
This bill is one of many.
Codify tracks hundreds of bills on Criminal Justice across all five countries.
Explore Criminal Justice in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Anti‑abortion advocacy organizations — They achieve a statutory federal prohibition targeting medication abortion and a definitional framing (pregnancy begins at fertilization) that supports their legal goals.
- Clinicians and facilities that provide surgical abortion services — They may face reduced local competition from medication‑based providers if enforcement or widespread compliance reduces availability of medication abortion.
- State authorities and prosecutors favoring criminal enforcement — Federal law provides an additional tool and a uniform statutory vehicle for pursuing conduct that some states also seek to restrict (or that some states may be unable to reach due to state law constraints).
Who Bears the Cost
- Manufacturers of mifepristone, misoprostol, and other products used for medication abortion — They face criminal exposure for distribution intended to procure abortions and potential disruption to markets, supply chains, and labeling practices.
- Pharmacies, especially mail‑order and retail chains, and telemedicine platforms — These entities will confront compliance uncertainty about filling remote prescriptions and shipping medicines across state lines and may curtail services to avoid criminal exposure.
- Healthcare providers who prescribe medication abortion — Clinicians will face criminal risk for standard-of-care prescribing practices unless they fit into the statute’s narrow exceptions, likely chilling telehealth and routine medical management.
- Federal enforcement agencies and courts — DOJ, federal prosecutors, and courts would shoulder the burden of enforcing complex medical‑intent crimes and resolving conflicts with FDA determinations and state law, creating resource and doctrinal strains.
Key Issues
The Core Tension
The statute pursues a clear objective—criminally prohibiting chemical abortion to protect fetal life from fertilization onward—but it does so by converting a regulatory and medical question into a federal crime, creating a clash between public‑health practice/FDA authority and criminal enforcement; the core dilemma is whether protecting nascent fetal life justifies substituting criminal law for the nuanced, risk‑based regulatory framework and clinical judgment that currently govern medication use.
The bill’s ‘‘notwithstanding any other provision of law’’ clause attempts to make the federal prohibition operative even where FDA authorizations or other statutes permit distribution; that creates a direct legal clash between federal criminal law and the federal administrative regime that currently governs drug safety and labeling. Courts will face novel preemption and inter‑branch separation questions: can Congress effectively criminalize conduct that FDA approves and regulates, and if so, how should courts reconcile conflicting federal statutes and agency action?
The text provides no mechanism for harmonizing criminal enforcement with FDA’s risk‑benefit determinations or labeling exceptions.
The mens rea element—prohibiting acts done “for the purpose of procuring an abortion”—will produce evidentiary and practice‑management problems. Proving a provider’s specific purpose in clinical settings is often complex: medications have multiple clinical uses and the same drug may be legitimately used for miscarriage management or other obstetric conditions.
The miscarriage exception depends on medical guidelines “as accepted as of the date of the miscarriage,” a temporally contingent standard that could expose clinicians to after‑the‑fact second‑guessing about whether they followed contemporaneous norms. Finally, defining pregnancy from fertilization and tying ‘‘unborn child’’ to a Title 1 notion of born‑alive adopts a biological starting point that will ripple into issues of research, contraception counseling, and diagnostic practice where the timing of conception versus implantation matters.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.